Epithelial ovarian neoplasms are a heterogeneous group of tumors, including various malignancies with distinct clinicopathologic and molecular features. Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors. Implementation of targeted therapeutic strategies requires access to highly specific and highly sensitive diagnostic tests for rapid determination of mutation status. One candidate for such test is fully integrated, real-time polymerase chain reaction-based Idylla™ system for quick and simple detection of KRAS mutations in formaldehyde fixed-paraffin embedded tumor samples. The primary aim of this study was to verify whether fully integrated real-time polymerase chain reaction-based Idylla system may be useful in determination of KRAS mutation status in patients with borderline ovarian tumors and low-grade ovarian carcinomas. The study included tissue specimens from 37 patients with histopathologically verified ovarian masses, operated on at the Department of Obstetrics and Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz (Poland) between January 2009 and June 2012. Based on histopathological examination of surgical specimens, 30 lesions were classified as low-grade ovarian carcinomas and 7 as borderline ovarian tumors. Seven patients examined with Idylla KRAS Mutation Test tested positive for KRAS mutation. No statistically significant association was found between the incidence of KRAS mutations and histopathological type of ovarian tumors. Mean survival of the study subjects was 48.51 months (range 3-60 months). Presence of KRAS mutation did not exert a significant effect on the duration of survival in our series. Our findings suggest that Idylla KRAS Mutation Test may be a useful tool for rapid detection of KRAS mutations in ovarian tumor tissue.
Introduction
Epithelial ovarian neoplasms are a heterogeneous group of tumors, including various malignancies with distinct clinicopathologic and molecular features. For many years, epithelial ovarian cancer was considered to be a single disease originating from ovarian surface epithelium or epithelium of cortical inclusion cysts, and having potential for divergent differentiation resulting in common occurrence of mixed tumors. Based on differences in clinical phenotype and genetic background, ovarian neoplasms are classified as low-grade and high-grade tumors. 1 A large body of evidence suggests that the most common subtype of ovarian malignancy, high-grade serous carcinoma, usually originates from the epithelium of the distal fallopian tube. 2, 3 In turn, the majority of clear-cell and endometrioid carcinomas arise from endometriosis, and most low-grade serous cancers originate from serous borderline tumors. 4 Better understanding of ovarian cancer risk factors and pathogenesis will likely contribute to earlier detection and better prevention of this malignancy and is fundamental for development of more effective therapies. The need for accurate histologic classification is particularly important in the current era of personalized therapy, when histologic type of a malignancy is frequently listed as an inclusion criterion of many clinical trials. Molecular testing still did not become a routine component in ovarian cancer management; however, this may soon change, as molecular biomarkers of this malignancy are a subject of extensive research. Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas, serous borderline tumors, and mucinous cancers. 5 Low-grade serous carcinomas with KRAS mutation seem to be more aggressive and more likely to recur than BRAF-positive malignancies. 6, 7 Both KRAS and BRAF are involved in RAS-RAF-mitogen/extracellular signal-regulated kinase (MEK), extracellular signal-regulated kinase (ERK), and mitogen-activated protein kinase (MAPK) pathways that regulate cell proliferation. 8 Determination of molecular profile of the ovarian tumor requires access to highly specific and highly sensitive diagnostic tests for rapid determination of mutation status.
One candidate for such test is the fully integrated real-time polymerase chain reaction (RT-PCR)-based Idylla™ system for quick and simple detection of KRAS mutations in formaldehyde fixed-paraffin embedded (FFPE) tumor samples. 9 Idylla KRAS Mutation Test can detect 21 KRAS mutations: 7 mutations in codons 12 and 13 (exon 2), 9 mutations in codons 59 and 61 (exon 3), and 5 mutations in codons 117 and 146 (exon 4). The results are obtained quickly, and the risk of PCR contamination is limited to a minimum due to the closed nature of the cartridge. To the best of our knowledge, none of the previous studies analyzed application of the Idylla system in detection of KRAS mutations in patients with borderline ovarian tumors and ovarian carcinomas.
The primary aim of this study was to verify whether, fully integrated RT-PCR-based Idylla system can be used for rapid determination of KRAS mutation status in patients with borderline ovarian tumors and low-grade ovarian carcinomas.
Material and methods
The study included tissue specimens from 37 patients with histopathologically verified ovarian masses, operated on at the Department of Obstetrics and Gynecology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz (Poland) between January 2009 and June 2012. All patients underwent surgical resection appropriate to the clinical stage of their malignancy and, whenever necessary, received adjuvant platinum-based chemotherapy in line with current Polish guidelines. 10 Based on histopathological examination of surgical specimens, 30 lesions were classified as low-grade ovarian carcinomas and 7 as serous borderline ovarian tumors. Probability of 5-year survival was analyzed in relation to clinicopathological features. Clinicopathological characteristics of the study subjects are summarized in Table 1 .
Molecular studies of FFPE specimens were conducted at the Department of Clinical Pathology, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz.
Idylla system is a fully automated molecular (CE-IVD) diagnostic platform (Biocartis, Mechelen, Belgium). Biocartis' Idylla KRAS Mutation Test is suitable for detection of KRAS mutations from FFPE tissue sections. The test was shown to detect 21 clinically relevant KRAS mutations: seven mutations in codons 12 and 13 (exon 2), Prior to the analysis, each sample was verified by two independent pathologists, to confirm that at least 10% of tumor cells were present in every section. Each test included a single 10 µm section (with at least 50-mm 2 tumor area) of FFPE tissue. The specimen, protected by wet filter paper, was transferred to a cartridge and loaded to the Idylla instrument. During the test, isolated nucleic acids were separated to 5 PCR chambers via microfluidic channels inside the cartridge (Idylla KRAS). To provide appropriate RT-PCR amplification and detection, all reagents were used in a dry form. Allele-specific targets were identified with a fluorescence-based detection system. The result was available after approximately 130 min. Idylla software calculated quantification cycle (Cq) value for each valid PCR curve. Presence of a mutant genotype was determined based on the difference between Cq for wild-type KRAS and Cq for the PCR signal(s) of KRAS mutant. KRAS total, that is, wild-type gene, was used as a sample processing control, and colorectal cancer specimen with established KRAS mutation served as a positive control. The results were presented as "KRAS mutation detected," along with a specific mutation type, or "no mutation detected."
The protocol of the study was approved by the Local Bioethics Committee at the Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz (decision no. KB 413/2016), and written informed consent was sought from each patient or their next of kin. Statistical analysis of the results was carried out with PQStat ver. 1.6.2.901 package. Regarding potential association between the incidence of KRAS mutations and histopathological type of ovarian tumor, the calculations were carried out with permutation Fisher test. Overall survivals were obtained as life-table and Kaplan-Meier estimates, and compared with log-rank, Wilcoxon-Breslow-Gehan, and Tarone-Ware tests. Potential predictors of survival were identified in Cox proportional-hazards regression model. The results were considered significant at p < 0.05 and highly significant at p < 0.01.
Results
The study included 37 patients with mean age of 54.19 years (range 27-80 years). Seven patients examined with Idylla KRAS Mutation Test tested positive for KRAS mutation. Three patients from this subset had serous borderline tumors; two of them carried KRAS mutations in codon 12 G12D (p.Gly12Asp; nucleotide: c35G>A) and one in codon 12 G12A (p.Gly12Ala; nucleotide: c35G>C). Another two KRAS mutations, in codon 12 G12A (p.Gly12Ala; nucleotide: c35G>C) and in codon 12 G12V (p.Gly12Val; nucleotide: c35G>T) were detected in lowgrade serous ovarian carcinomas. Finally, two patients, one with low-grade mucinous carcinoma and another with low-grade endometrioid carcinoma, carried KRAS mutations in codon 12 G12V (p.Gly12Val; nucleotide: c35G>T). Representative PCR curves and corresponding Cq values are shown in Figures 1-4 .
No statistically significant association was found between the incidence of KRAS mutations and histopathological type of ovarian tumors (p > 0.05; Table 2 ). Mean survival of the study subjects was 48.51 months (range 3-60 months). Presence of KRAS mutation did not exert a significant effect on the duration of survival in our series.
Overall survivals were obtained based on life tables and Kaplan-Meier estimates, and compared with log-rank, Wilcoxon-Breslow-Gehan, and Tarone-Ware tests. The results are shown in Table 3 . Irrespective of the statistical tests, presence of KRAS mutation exerted no significant effect on survival time. Statistical power of the log-rank test was estimated at 0.55.
Discussion
Biological mechanisms leading to malignant transformation of ovarian surface epithelium are still not completely understood. Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors. 11 The RAS oncogene family comprises three principal members, KRAS, HRAS, and NRAS. All these genes have been implicated in the development of human malignancies. KRAS, located on chromosome 12p12, encodes a 21-kD protein (p21RAS) involved in MAP-kinase signal transduction pathway, responsible for control of cellular proliferation and differentiation. Presence of KRAS mutation contributes to constitutive activation of this signal transduction pathway and resultant uncontrolled proliferation and differentiation of cells. 12, 13 A plethora of previous studies documented presence of activated forms of KRAS in human malignancies from various locations, inter alia pancreas (60%), biliary tract (32%), large and small intestine (32% and 20%, respectively), gastrointestinal tract (indeterminate location, 19%), thymus (15%), and endometrium (14%). 14 The incidence of KRAS point mutations in epithelial ovarian carcinomas is estimated at 15% to 39%. 14, 15 KRAS and BRAF mutations have not been found in early-stage serous cystadenomas, 16 but were detected in borderline serous tumors, as well as in adjacent cystadenoma epithelium of serous cystadenomas associated with small borderline tumors. 17 While these mutations are present in serous borderline tumors and in either noninvasive or invasive micropapillary serous carcinomas, they are absent in high-grade serous carcinomas; this implies that at least two distinct pathways exist in serous ovarian carcinogenesis. 18, 19 KRAS/NRAS mutations are relatively frequent in advanced/recurrent low-grade serous cancers. 20 Presence of KRAS mutations was also documented in mucinous, clear-cell, and endometrioid ovarian carcinomas. [21] [22] [23] In this study, we found KRAS mutations in 7/37 patients with borderline ovarian tumors and low-grade ovarian carcinomas. No statistically significant relationship was observed between the incidence of KRAS mutations and histopathological type of ovarian malignancies. According to literature, KRAS and BRAF mutations are detected in approximately a third of borderline ovarian tumors and in a third of low-grade ovarian serous carcinomas. 24 However, KRAS and BRAF mutations never coexist within the same tumor, which suggests that they are mutually exclusive. This hypothesis is also supported by the results of our present and previous studies; while we found BRAF or KRAS mutations in 6 out of 7 serous borderline tumors examined with the Idylla Mutation Test, these genetic defects were never present within the same specimen. 25 Although the impact of KRAS mutation on survival in ovarian malignancies is yet to be established, several previous studies found no correlation between these two parameters, 26 and only few authors demonstrated a significant inverse relationship between them on multivariate analysis. 27 Similar to most previous studies, we did not find a statistically significant association between the presence of KRAS mutation and 5-year survival rate in our group of patients with borderline ovarian tumors and lowgrade ovarian carcinomas. Point mutations in cancer cells can be detected with a number of various methods, including PCR, direct sequencing, multiplex PCR and array hybridization, and amplification-refractory mutation systems. The most popular method for molecular characterization of genetic variants is direct sequencing, which can detect all potential variations, including base substitutions, insertions, and deletions. However, direct sequencing has some limitations when applied to clinical samples. First, it is not sensitive enough (10%-30% level) to detect specific point mutations. 28 Analytic sensitivity of this method can be improved by pyrosequencing, high-resolution melting analysis, real-time, or allele-specific PCR assays. 29, 30 Next-generation sequencing methods have high analytic sensitivity, offer broad reportable range of mutation spectrum, and provide adequate capacity in quantitative measurement of mutant allele frequencies and simultaneous detection of concomitant mutations. 31 One of such novel methods suitable for detection of KRAS mutations is peptide nucleic acid-locked nucleic acid-mediated loop-mediated isothermal amplification (PNA-LNA mediated LAMP). Advantages of this non-PCR DNA amplification technique include high sensitivity and short reaction time, no longer than 50 min. 32, 33 Direct sequencing is still the best method to detect changes in codons 12 and 13 of KRAS gene, providing accurate information about the type of genetic anomalies, including nucleotide variant of the mutation. However, the quality of tests involving paraffin-embedded tissue specimens may be very low. Potential drawbacks of such tests include lack of amplification or ambiguous outcome of the sequencing associated with abundance of nonspecific background, resulting from DNA degradation. Another potential problem is the small quantity of cell clones in codons 12 and 13, resulting in the presence of low fluorographic peaks, hardly distinguished from the background. 34 Information about molecular profile of the tumor, including its KRAS mutation status, is currently used to optimize treatment of various malignancies, among them colorectal cancer, 35, 36 non-small-cell lung cancer, 37 and pancreatic cancer. 38 Selection of an adequate targeted therapy on the basis of the result of molecular testing stimulated progress in treatment of various malignancies. Molecular testing has helped to identify patients who will most or least likely benefit from a given therapy, and accelerated the process of novel drug development.
Application of direct sequencing as a routine method for cytological diagnosis in a hospital setting requires implementation of complicated procedures and purchase of expensive equipment. Another limitation of this method in everyday clinical practice is long analytical times. This stimulated a search for a simple, rapid, specific, and sensitive methodology to detect point mutations. Recently, some new molecular assays for detection of KRAS mutations have become available. These are fully automated molecular diagnostic systems for quantitative allele-specific RT-PCR-based analyses. Unlike currently available technologies for KRAS mutation detection, Idylla KRAS Mutation Test does not require manual preprocessing of the sample, that is, deparaffinization, digestion of FFPE tissue, or DNA extraction, since all these procedures are integrated within a single-use cartridge. 39 Instead, whole FFPE tissue sections or macro-dissected FFPE specimens are inserted into the cartridge and processed by the Idylla system; also further stages, that is, RT-PCR-based mutation detection and result reporting, are fully integrated and automated. 40 Without the need for highly skilled staff, mutational tests approved by the European Community for in vitro diagnostic use (labeled as CE-IVD) can genotype KRAS with a 5% detection limit, which allows for their use as a standardized method, even at diagnostic centers without a developed molecular infrastructure. 41 Idylla KRAS Mutation Test can be used for detection of KRAS mutations directly from FFPE tissue specimens in approximately 2 h, with less than 2-min hands-on time. While the cost of a single Idylla cartridge is relatively high, this method does not require preprocessing of the sample, necessary in the case of other conventional techniques, and frequently representing a hidden cost. 42 According to Colling et al., 43 Idylla System is a simple, time-and costeffective method for molecular testing, but has an important limitation, namely that it detects only the dominant mutation for a given specimen. 44 If the result of the test is ambiguous, in line with the rules of good laboratory practice, the presence of the mutation or lack thereof should be confirmed with two independent, adequately sensitive and accurate methods. 34 Our findings suggest that Idylla KRAS Mutation Test may be a useful tool for rapid detection of KRAS mutations in ovarian tumor tissue. Introduction of personalized therapies has changed standards of care in selected cancer patients; presence of a critical somatic mutation in cancer cells improves accuracy of the diagnosis and prognosis, which eventually produces both health and economic benefits. This study demonstrated that the fully automated molecular diagnostic system Idylla is a promising tool for detection of KRAS mutations in histological specimens. Using this instrument, even pathologists from less experienced laboratories can easily integrate morphological findings with molecular data, which is crucial for further diagnostic and therapeutic decisions.
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